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“And thick and fast they came at last 
And more, and more, and more . . . ” 
Alice Through the Looking Glass 
Lewis Carroll 
T he causal relationship between the rise in activity of certain enzymes in 
the serum and the occurrence of damage to 
the myocardium has been established with- 
out question. Experiments and histochemi- 
cal investigations have shown that in- 
farcted heart muscle is rapidly depleted of 
various enzymes, and that these enzymes 
appear in an active form in the blood that 
drains from the infarcted myocardium. 
Rapid clinical utilization of these ob- 
servations followed the report by LaDue 
and associates1 in 1954, that serum glu- 
tamic oxalacetic transaminase (SGOT) is 
elevated after an acute myocardial infarct. 
As indicated in the preamble to this report, 
many other enzymes have been tested for 
their applicability in the confirmation of 
the diagnosis of myocardial infarct. The 
myocardium is a rich source of enzymes, 
and, in addition to SGOT, elevations of 
the malate and lactate dehydrogenases, 
aldolase, phosphoglucose isomerase, and 
creatine phosphokinase are usually present 
after infarction of cardiac muscle. 
To the present time, however, only five 
enzymatic assays have withstood critical 
clinical and laboratory investigation. These 
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are the measurement of (1) serum glutamic 
oxalacetic transaminase (SGOT) ; (2) serum 
lactic dehydrogenase (SLD) ; (3) isoen- 
zymes of serum lactic dehydrogenase; (4) 
serum a-hydroxybutyric dehydrogenase 
(SHBD) ; and (5) serum creatine phos- 
phokinase (SCPK). 
Transaminases. Human tissues and serum 
contain two transaminases of clinical im- 
portance: SGOT and glutamate-pyruvate 
transaminase (GPT). They catalyze the 
reversible transfer of an amino (NHJ group 
from an amino acid to a receptor keto acid, 
yielding a new amino acid and a new keto 
acid : 
Aspartate + ketoglutarate s Glutamate 
+ oxalacetate 
Alanine + ketoglutarate s Glutarate i- 
pyruvate 
The heart and liver are especially plenti- 
ful in GOT, but the liver contains much 
more GPT than does the heart. Thus, the 
SCOT may be expected to be increased 
when either of these organs is damaged, 
but an elevation of SGPT is typical of 
hepatocellular damage only. 
Lactic dehydrogenase. This enzyme is 
widely distributed throughout most body 
tissues and catalyzes the reaction: 
Lactate + nicotinamide - adenine dinucleotide 
(NAD) s pyruvate + reduced nicotinamide 
- adenine diculeotide (NADHg) 
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Fig. 1. Densitometric tracing of a lactic dehydro- 
genase electropherogram obtained from a patient 
manifesting an acute myocardial infarct. Note (1) 
the elevated fast (anodic) isoenzymes and (2) the 
clear discrimination between these “myocardial” 
fractions and the cathodic-hepatic isoenzymes. 
Lactic dehydrogenase isoenzymes. Lactic 
dehydrogenase, in consort with other en- 
zymes, is not a uniform enzyme, but rather 
occurs in a number of molecular species. 
These differ in their primary structure, i.e., 
amino acid sequence, yet possess the same 
action and substrate specificity (L-lactate). 
The enzymatically active fractions (iso- 
enzymes or isozymes) can be separated by 
a variety of means. Under the conditions 
of electrophoresis (starch gel, agar gel, or 
cellulose acetate), normal human serum is 
separable into five distinct isoenzymes.2 
Tissues with a high aerobic metabolism, 
such as cardiac muscle, have a high con- 
tent of fast-migrating (anodic) isoenzymes. 
Conversely, slow-migrating (cathodic) frac- 
tions predominate in the liver.3 The heart 
and liver fractions occupy extreme poles 
of the isogram and may be readily dis- 
tinguished (Fig. 1). 
The five isoenzymes are produced by a 
random tetramic association of two dif- 
ferent polypeptide subunits which are 
considered to be under separate genetic 
control.’ The first and fifth are homo- 
geneous tetramers, whereas the three inter- 
mediate bands are heterogeneous or “hy- 
brid forms.” This suggests that, in fact, 
only two principal or parent forms of LDH 
exist. All possible combinations of these 
two monomers are produced (Table I). 
The clinical, laboratory, and diagnostic 
importance of this molecular heterogeneity 
lies in the fact that a differential evaluation 
of an elevated total SLD may be possible 
Table I. Tetramic molecular association of 





AA AB AB BB BB 
AA A24 AB AB BB 
LDHl LDHz LDHa LDHa LDHs 
when there is concomitant injury to sev- 
eral tissues. 
‘ ‘Alpha-hydroxybutyric dehydrogenase” 
(HBD). It has been shown that lactic de- 
hydrogenase does not possess an absolute 
specificity for its usual substrate, but can 
also convert the oxo-group of ketobutyric 
acid in the alpha position to the hydroxy 
group.5 The fast-migrating SLD isoenzymes 
exhibit much greater ability than do the 
slow fractions to reduce a-ketobutyrate 
relative to their activities with pyruvate as 
substrate. In deference to the reaction with 
a-ketobutyrate, the “catalyst” has been 
designated “~hydroxybutyric dehydrogen- 
ase” (HBD).!’ At present, it is not known 
what kind of enzyme one is measuring 
when the assay for SHBD activity is per- 
formed, but the measurement has been 
equated with a chemical differentiation of 
the fast-migrating SLD isoenzymes.6 
Creatine phosphokinase (UK). CPK cat- 
alyzes the reversible transfer of a high- 
energy phosphate group from adenosine 
triphosphate (ATP) to creatine : 
CPK 
ATP + creatine _ adenosine diphosphate 
(ADP) + creatine phosphate. 
The enzyme is found principally in 
skeletal and heart muscle, and also, in lesser 
amounts, in brain tissue. Kidney, liver, 
lung, pancreas, and the erythrocytes have 
virtually undetectable amounts of CPK 
activity.? The distribution in human tissue 
has led to the consideration of serum CPK 
activity as the “most specific and sensitive 
serum enzyme test currently available for 
the confirmation of disease or injury to 
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skeletal muscle and myocardium.“7 In dis- 
eases of skeletal muscle, with particular 
reference to the dystrophies, the estima- 
tion of CPK is the measurement of choice, 
and studies in patients with muscular dis- 
orders underscore the value of estimations 
of CPK in the differential diagnosis be- 
tween progressive muscular dystrophy and 
atrophies of neurogenic origin.8 
Clinical application 
Any evaluation of the clinical applica- 
bility of an enzyme assay must perforce 
be a consideration in three fundamental and 
interrelated areas of consideration : (1) 
ease of assimilation into the diagnostic 
laboratory, (2) specificity and sensitivity of 
the enzyme being measured, and (3) dura- 
tion of the enzyme’s activity in sera after 
tissue injury. 
Laboratory fierformance. The estimation 
of the activity of SGOT, SLD, and SHBD 
may be determined satisfactorily by either 
spectrophotometric or calorimetric assays. 
The former has inherent “chemistry” 
Table II 
GOT activities of CPK activities of 
human tissues*‘5 human tissuest7 
Heart 7,800 Skeletal muscle 18,400 
Liver 7,100 Heart 5,550 
Skeletal muscle 5,000 Brain 3,400 
Kidnel 4,500 Adrenal gland 136 
Pancreas 1 ,400 Lung 0.5 
Spleen 700 Liver 0 
1,ung 500 Prostate 0 
Red blood cell 15 Red blood cell 0 
Serum 1 Serum 0 
*Relative activity referred to serum as unit. 
tlkpressed as mean activity of soluble protein (units (X lOa)/ 
m&Z.). 
Table III. Normal erythrocyte and serZLm 
content of enzyme activity 
1 GOT/ LDH ~ HBD / CPR 
RBC/serum content 8/l 1,000/l 1,000/l 0 
Lrdvantages, In t equal clinical informa- 
tion is derived from both types of assay. 
As of the present, calorimetric assays 
of CPK cannot be recommended and 
are distinctly inferior to ultraviolet spec- 
trophotometric methods.” 
The electrophoretic separation of SLD 
isoenzymes is diagnostically superior to 
techniques relying on heat stability of the 
fractions. Cellulose acetate fractionation is 
within the technical ability of any routine 
laboratory and is readily suited for either 
a quantitative or qualitative evaluation 
after separation of the isoenzymes.3 
Enzyme specificity. There is no enzyme 
activity measurable in serum which is 
specific for heart muscle alone. Specificity 
then becomes a subject of relative evalua- 
tion. In decreasing order of relative spe- 
cificity, the enzymes may be listed as fol- 
lows: CPK, isoenzyme of LDH, SHBD, 
SGOT, and SLD. 
The nonspecificity of SLD is well known. 
Table II, listing the tissue activity levels 
of CPK and GOT, may he considered to 
represent the two extremes of the relative 
specificity scale. Table I I I emphasizes 
the absence of CPK activity within the 
erythrocyte, a very important feature when 
one is considering the effect of hemolysis 
on serum activit1, levels. 
Early reports at tested to a high degree of 
specificity for heart muscle manifested by 
cu-hydroxybutJ.ric dehydrogenase.‘“,” As 
clinical and diagnostic experience with the 
assay was gained, this enhanced specificit) 
leas found to I)e only relative, albeit supe- 
rior to the measurements of SGOT and 
SLI).” Fig. 2 indicates that elevations 
above normal may occur in a variety of 
disorders other than myocardial infarct. 
Elliott and Wilkinsonj have resorted to 
the use of an SHBD/SLl> ratio in the 
differentiation of myocardial disease from 
other disorders in which the SHBD is ele- 
vated. Investigation in our laboratories,6 
and that of RosalkilB have not substanti- 
ated this discriminatory capacity of the 
ratio. 
Fractionation of the isoenzymes of lactic 
dehydrogenase has markedly increased the 
sensitivity and specificity of that enzyme 
in clinical diagnosis. The various fractions 
have been designated numerically accord- 
ing to their primary sources as follows’3: 
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S.H. 8. D. ACTIVITY LEVELS IN CLINICAL DISODERS 
Fig. 2. Although SHBD activity may be considered to be more specific for myocardial lesions than the SGOT 
or SLD, false positive levels are seen in hepatobiliary disorders, congestive heart failure, and hematopoietic 
disorders, especially hemolysis. Note, however, the absence of false negatives in the 66 cases of documented 
myocardial infarct. In the University of Michigan series, all infarcts have produced activity levels above 120 
1 from skeletal muscle and liver, 2 and 3 
from lungs, 3 and 5 from the pancreas, 
3 and 4 from the lungs, 3, 4, and 5 from the 
kidney, 4 and 5 from cardiac muscle, 
In actual laboratory and clinical practice, 
similar and often identical patterns for 
myocardial infarct are seen in patients 
manifesting infarcts of the kidney, patients 
with pernicious anemia or lymphomas with 
hemolytic anemia, and patients suffering 
from progressive muscular dystrophy.3 To 
emphasize the effect of hemolysis, a com- 
mon practice is to use hemolyzed serum as a 
positive control for electrophoretic separa- 
tions. 
Enzyme sensitivity. Under the proper 
conditions of appropriate selection of test 
and due consideration of the duration of 
activity in sera, all five procedures will yield 
positive results. False negatives are rare 
and may be attributed to laboratory error 
in most instances.14 SLD isoenzyme frac- 
tionation appears to have a superior sensi- 
tivity. The appearance of a positive in- 
crease in the fast fractions may antedate 
both electrocardiographic changes and a 
rise in the total enzyme activity in the 
serum. Ten from our series of over 2,000 
isograms have manifested this phenome- 
non, and the experience of Freeman and 
Opher13 corroborates these observations. 
Reliance on the estimation of the total 
activity in sera alone may be misleading in 
the discrimination between superimposed 
congestive heart failure and a second in- 
farct or extension of the primary myocar- 
dial infarct. In these instaqces, isoenzyme 
fractionation and/or estimation of CPK 
dffer considerable assistance: in the former, 
by the emergence of a hepatic band in the 
isogram, and in the latter by an additional 
“peaking” after normalization has oc- 
curred. The absence of CPK in the liver 
makes a secondary rise in activity almost 
pathognomonic of a superimposed or ex- 
tended myocardial infant. 
Enzyme release and duration of activity. 
After an initial elevation following myo- 
cardial infarction, enzyme activity in 
serum declines rather rapidly and the half- 
‘78 /ht.wkis und Rriere 
Ttrhle 11;. Reaction time or release-trctivity 
span irz serum after uncom#icuted myo- 
cordial infarction 
Onset of rise 12 hr. 12-24 hr. 12-24 hr. 3-4 hr. 
Return to 
normal 4 days 7 days 10 days 3 days 
Peak X normal 4.2 3.6 4.8 11 
Time of peak 24 hr. 72 hr. 72 hr. 33 hr. 
lives of the enzymes important in the diag- 
nosis of myocardial infarct are short, i.e., 
the enzymes are rapidly eliminated or in- 
activated. It may be seen then that, al- 
though a normal serum activity level in the 
course of serial determinations excludes the 
presence of a “fresh” or superimposed in- 
farct, it does not, depending upon the time 
of collection, exclude the diagnosis of an 
initial myocardial infarct. 
Table IV summarizes the average time- 
reaction span and “peaks” of the serum 
activity of four of the five enzyme assays 
under consideration. After a myocardial 
infarction, activity increases in the serum 
in the folloning order: (1) CPK, (2) 
(XX, (3) LD, and (4) HBD. The re- 
turn to normal levels also follows this 
sequence. Serum CI’K begins to rise before 
any of the others, often as early as 3 to 
4 hours after the infarction. Peak activity 
is usually reached at 36 hours, followed by 
a rather precipitous drop to normal levels 
by the second to the fourth day. The length 
of time during which SGOT is elevated 
after the infarction is relatively short-m- 
average of 4 to 5 days-and, although SLD 
is elevated for a longer time, SHBD re- 
mains at abnormal levels the longest--l0 
to 15 days. Large myocardial infarcts ma) 
cause persistence of abnormal levels of 
SHBD for as long as 5 to 10 days after the 
total enzyme activity of SLD has normal- 
ized13J4 (Fig. 3). If restricted to the choice 
of one specimen, it would appear to be 
wisest to delay sampling until the period 
24 to 36 hours after infarction. It is this 
time period which will give the greatest 
likelihood of obtaining abnormal values 
for all enzyme activity. 
Conclusions 
There is no enzyme activity measurable 
in serum which is specific for myocardial 
DAYS POST MYOCARDIAL INFARCT 
Fig. 3. Graphic depiction of serial isoenzymes and SLD and SHBD activities in the serum from a patient mani- 
festing an uncomplicated myocardial infarct. Note the persistence of elevated levels of SHBD and positive 
isograms a&r the normalization of SLD. 
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infarction. Of the five most applicable 
enzymatic procedures @GOT, SLD, SLD 
isoenzymes, SHBD, and CPK) for the 
confirmation of the diagnosis of myocardial 
infarct, the estimations of CPK and the 
fractionation of SLD isoenzymes enjoy the 
greatest degrees of specificity and sensi- 
tivity. 
Specificity and sensitivity notwithstand- 
ing, the single most important variable in 
the diagnostic application of the tests is the 
time of collection of the sample in relation 
to the clinical history. False negatives are 
the rare exception if the appropriate test is 
used in the light of activity spans in serum. 
Estimations of CPK are most useful in 
the acute clinical situations, since a rise in 
its activity may precede that of the other 
enzymes by 8 hours. All measurements will 
be positive within 24 to 36 hours after the 
onset of the infarction. The major signifi- 
cance of estimations of SHBD resides in the 
fact that its activity persists after other 
activity levels have returned to normal. 
Isoenzyme fractionation and serial esti- 
mations of CPK, because of their enhanced 
discriminatory ability, are superior to all 
other enzyme tests for purposes of differ- 
ential diagnosis and prognostic follow-up 
evaluation. 
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